Currently Viewing:
Evidence-Based Oncology Patient-Centered Oncology Care: Real-World Perspectives 2013
The Angelina Effect: Rising Interest in Genetic Testing Creates Opportunities for Patients-and Profit
Ellen T. Matloff, MS
Faculty Index
Person-Centered Care: The New Business Case for Cancer
Amy Berman, BS, RN
Will Shifts in Oncology Outpatient Points of Care Lead to More Profits or Savings?
Peter B. Bach, MD, MAPP
Care Reflects Patient Choice, but Having the Data Reflect 'Consumerism' Is Another Matter
Cliff Goodman, PhD; Amy Berman, BS, RN; Dennis Scanlon, PhD; and Manasi A. Tirodkar, PhD, MS,
When Making Decisions in Cancer Care, Patients Want to Know: How Will I Feel?
Ethan Basch, MD
Cancer Patients Need Better Information, and Payers Should Demand They Receive It
Cliff Goodman, PhD; A. Mark Fendrick, MD; John L. Fox, MD, MHA; and Ira M. Klein, MD, MBA, FACP
Currently Reading
Measures That Improve Quality Must Be Nimble if Imperfect, UnitedHealthcare's Newcomer Explains
Lee N. Newcomer, MD, MHA
Can Clinical Pathways Change the 'Culture' in Cancer Care?
Bruce A. Feinberg, DO
Payer Perspectives in Genetic Counseling
Karen Lewis, MS, MM, CGC
Grappling With the Fallout of Genetic Testing, in Oncology and Beyond
Ira M. Klein, MD, MBA, FACP; Jan Berger, MD, MJ; Michael A. Kolodziej, MD
The Present-and Future-of Genetic Profiling in Oncology
Jerry Conway
Next-Generation Sequencing in Oncology: Are We Ready for Prime Time?
Lee N. Newcomer, MD, MHA; Michael A. Kolodziej, MD; John L. Fox, MD, MHA; Ira M. Klein, MD, MBA, FACP
Putting the 'Economics' Back Into Health Economics Outcomes Research
Scott D. Ramsey, MD, PhD
Value-Based Pricing: The Role of Outcomes Data in Pricing Models
Michael E. Chernew, PhD; Cliff Goodman, PhD; Jeffrey D. Dunn, PharmD, MBA; Kirby Eng, RPh
Redefining the Role of Industry in Contemporary Healthcare
John L. Fox, MD, MHA; Bo Gamble; and Cliff Goodman, PhD

Measures That Improve Quality Must Be Nimble if Imperfect, UnitedHealthcare's Newcomer Explains

Lee N. Newcomer, MD, MHA
Lee N. Newcomer, MD, MHA, senior vice president for Oncology, Genetics and Women's Health at UnitedHealthcare, spoke on Defining and Measuring Quality Outcomes in Oncology.
Lee N. Newcomer, MD, MHA, senior vice president for Oncology, Genetics and Women’s Health at UnitedHealthcare, spoke next on “Defining and Measuring Quality Outcomes in Oncology.”
Not long ago, a cancer care provider asked to measure quality would eschew attempts to take on the task, and declare that they would know quality when they saw it. That time has passed, said Lee N. Newcomer, MD, MHA, but what measurements will fill the void?

Newcomer, the senior vice president for Oncology, Genetics and Women’s Health at UnitedHealthcare, said that while oncology has accepted the need for measures of quality, deciding what they will be remains a work in progress. He outlined how to get beyond “process” measurements and take on the real cost drivers.

First, in Newcomer’s view, measurements used for accreditation or reimbursement are so heavily vetted that they become worthless. Second, measurements that can bring quality improvement quickly are necessarily imperfect, but perfection is not point. Changing behavior is, and he described how “organic” measurements are more valuable, as they can be changed midcourse if payers realize they are not capturing the right information.

UnitedHealthcare has created a database of information collected from its oncology providers. Newcomer said the insurer asked about the cost of a single course of specialty drugs—and providers were asked to fill out a form requesting information on histology, disease stage, gene tests, relapses, and current status of patients with breast, colon, lung, and prostate cancers. Most providers—70%—provided the data willingly. And now UnitedHealthcare has data on 65,000 patients, which it can use to spot trends and help providers make adjustments.

“You’re trying to move quickly here; you’re trying to find out how you can measure changes that you make in your processes, and being inclusive gets you numbers faster,” Newcomer said.

He offered this example: A hospital was told its readmission rates were too high after patients were treated for toxicity to chemotherapy. Leaving it up to the patient to call the clinic for follow-up appointments meant that many were not seen for 30 to 40 days. People got sick and had to be readmitted. After being told of the problem, the hospital worked to schedule follow-up visits 48 hours before discharge. Readmission rates are down.

“You need very instantaneous data to help people improve,” Newcomer said. That data should also be transparent; the public should have the ability to judge providers the same way payers do. Hospitals that don’t release data aren’t fooling anyone, Newcomer said, because payers can get it through their own means. As data collection becomes more commonplace and robust, there will be more data and more real-time assessments of quality, he predicts.

“The notion has been that patients aren’t smart enough to use that data correctly; they won’t risk-adjust, and I think that’s bologna,” Newcomer said.

Keys, he said, are for costs of care to be part of the quality equation, and for statisticians to be involved. An analysis of a clinic’s survival rates that doesn’t break down data by tumor type is less valuable than one that does, for example.

Newcomer also said that as payers collect and analyze more data, it may change just who or what is held accountable for quality. “If we can now look at outcomes, and if I can, as a payer, gather data on hundreds, if not thousands, of patients with a specific clinical diagnosis treated with several different regimens, we should be comparing the chemotherapy regimens, not the doctors,” he said. EBO
PDF
 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!